Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same
Inventors
Yoon, Seong Jun • JUN, Soo Youn • Jung, Gi Mo • Lee, Jin Hee • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12358953-B2
Publication Date
2025-07-15
Expiration Date
Abstract
An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.
Core Innovation
The invention relates to an antibacterial protein against Bacillus comprising the amino acid sequence of SEQ ID NO: 1. The described antibacterial protein is identified as BAL200, and the sequence is specified as 247 amino acids (about 26.5 kDa) as SEQ ID NO: 1.
The described protein BAL200 is characterized by selective lytic activity against multiple Bacillus species. The document describes lytic activity against Bacillus species and explicitly describes no lytic activity against several non-Bacillus bacteria.
The document further describes a pharmaceutical composition comprising BAL200 and indicates functional properties including lytic activity, biofilm eradication against Bacillus cereus, reduced immunogenicity in a human PBMC T-cell proliferation assay versus antibacterial protein B4, and in vivo therapeutic efficacy in a mouse infection model for Bacillus infections.
Claims Coverage
The independent claim set includes 1 independent claim. The independent claim covers the defined Bacillus antibacterial protein by sequence identity to SEQ ID NO: 1, with dependent claims refining the lytic activity profile, defining a pharmaceutical composition context, and specifying preparation/formulation constraints.
Antibacterial protein against Bacillus comprising SEQ ID NO: 1
An antibacterial protein against Bacillus comprising the amino acid sequence of SEQ ID NO: 1.
Coverage is anchored on the antibacterial protein sequence of SEQ ID NO: 1 (BAL200). Dependent claim refinements further constrain the lytic activity toward multiple Bacillus species, specify absence of lytic activity against several listed non-Bacillus bacteria, and associate the protein with a pharmaceutical composition context and defined preparation/formulation constraints.
Stated Advantages
Selective lytic activity against multiple Bacillus species while showing no lytic activity against several non-Bacillus bacteria.
Biofilm eradication against Bacillus cereus.
Reduced immunogenicity in a human PBMC T-cell proliferation assay versus antibacterial protein B4.
In vivo therapeutic efficacy in a mouse model for Bacillus infections, including improved survival and reduced morbidity signs.
Reduced impact on normal resident flora.
Documented Applications
Treatment of diseases caused by Bacillus genus.
Use in a mouse infection model for Bacillus infections, with improved survival and reduced morbidity signs.
Interested in licensing this patent?